These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16711554)

  • 21. Surveillance of the endometrium in tamoxifen treated women.
    Cardosi RJ; Fiorica JV
    Curr Opin Obstet Gynecol; 2000 Feb; 12(1):27-31. PubMed ID: 10752513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More on endometrial cancer and tamoxifen.
    Helzlsouer KJ; Bush T
    J Natl Cancer Inst; 1994 Dec; 86(24):1877. PubMed ID: 7990164
    [No Abstract]   [Full Text] [Related]  

  • 23. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature.
    Abudu EK; Musa O; Adefuye PO; Abdul Kareem FB; Agboola AO; Banjo AA
    Niger Postgrad Med J; 2007 Dec; 14(4):355-7. PubMed ID: 18163149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinicopathologic study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: a single center experience.
    Ravazoula P; Androutsopoulos G; Zyli P; Michail G; Kardamakis DM; Kourounis G
    Breast J; 2006; 12(6):578-84. PubMed ID: 17238994
    [No Abstract]   [Full Text] [Related]  

  • 25. High-grade endometrial stromal sarcoma following tamoxifen treatment.
    Engin H
    Gynecol Oncol; 2008 Jan; 108(1):253-4. PubMed ID: 17928038
    [No Abstract]   [Full Text] [Related]  

  • 26. Endometrial polyps in pre-and postmenopausal women: factors associated with malignancy.
    Cohen I
    Maturitas; 2008 Jan; 59(1):99-100. PubMed ID: 18162338
    [No Abstract]   [Full Text] [Related]  

  • 27. Mechanisms of action of antiestrogens: relevance to clinical benefits and risks.
    Carmichael PL
    Cancer Invest; 1998; 16(8):604-11. PubMed ID: 9844621
    [No Abstract]   [Full Text] [Related]  

  • 28. Tamoxifen and peripubertal women.
    Costello SA; Bassford C
    Australas Radiol; 1998 Nov; 42(4):397. PubMed ID: 9833388
    [No Abstract]   [Full Text] [Related]  

  • 29. Tamoxifen (TAM): the dispute goes on.
    Grilli S
    Ann Ist Super Sanita; 2006; 42(2):170-3. PubMed ID: 17033137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer.
    Georgopoulos NA; Adonakis GL; Fotopoulos A; Koika V; Spinos N; Saltamavros A; Keramopoulos A; Koukouras D; Decavalas G; Kourounis GS
    Gynecol Endocrinol; 2006 Apr; 22(4):185-9. PubMed ID: 16723304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed severe hypertriglyceridemia from tamoxifen.
    Kanel KT; Wolmark N; Thompson PD
    N Engl J Med; 1997 Jul; 337(4):281. PubMed ID: 9229698
    [No Abstract]   [Full Text] [Related]  

  • 32. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
    Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA;
    Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone builder vs. breast cancer.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen and endometrial lesions.
    Rayter Z; Shepherd J; Gazet JC; Trott P; Svensson W; A'Hern R
    Lancet; 1993 Oct; 342(8879):1124. PubMed ID: 8105355
    [No Abstract]   [Full Text] [Related]  

  • 36. Tamoxifen and endometrial lesions.
    McAuliffe FM; Foley ME
    Lancet; 1993 Oct; 342(8879):1124. PubMed ID: 8105354
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
    Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
    Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.